title: [Do endothelin receptors antagonists have a place in the treatment of arterial hypertension?].
abstract: The discovery in 1988 of endothelin, the most potent human endogenous vasoconstrictor, has opened the race to the discovery of a new weapon against arterial hypertension. The development of the endothelin receptors antagonists (ERAs) and the demonstration of their efficacy in preclinical models initially raised a wave of enthusiasm, which was however tempered due to their unfavorable side effect profile. In this article we will review the phases of the development ERAs, and their current and future place as therapeutic tool against arterial hypertension.
authors.affiliation: Service de néphrologie et hypertension, Département de medecine, CHUV, 1011 Lausanne. valentina.forni@chuv.ch
authors.forename: V
authors.initials: V
authors.lastname: Forni
authors.forename: G
authors.initials: G
authors.lastname: Wuerzner
authors.forename: M
authors.initials: M
authors.lastname: Pruijm
authors.forename: M
authors.initials: M
authors.lastname: Cassat
authors.forename: I
authors.initials: I
authors.lastname: Menetrey
authors.forename: M
authors.initials: M
authors.lastname: Burnier
mesh_terms: D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D065128:Endothelin Receptor Antagonists; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists